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In Brief
Production of the cytokine IL-18 by
epithelial cells, previously thought to
protect the mucosal barrier from the
effect of inflammation, is critical to drive
the pathologic breakdown of intestinal
barrier integrity, directly inhibiting goblet
cell maturation prior to the onset of colitis.
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The intestinal mucosal barrier controlling the resi-
dent microbiome is dependent on a protective
mucus layer generated by goblet cells, impairment
of which is a hallmark of the inflammatory bowel dis-
ease, ulcerative colitis. Here, we show that IL-18 is
critical in driving the pathologic breakdown of barrier
integrity in a model of colitis. Deletion of Il18 or its
receptor Il18r1 in intestinal epithelial cells (D/EC)
conferred protection from colitis and mucosal dam-
age inmice. In contrast, deletion of the IL-18 negative
regulator Il18bp resulted in severe colitis associated
with loss of mature goblet cells. Colitis and goblet
cell loss were rescued in Il18bp/;Il18rD/EC mice,
demonstrating that colitis severity is controlled at
the level of IL-18 signaling in intestinal epithelial cells.
IL-18 inhibited goblet cell maturation by regulating
the transcriptional program instructing goblet cell
development. These results inform on the mecha-
nism of goblet cell dysfunction that underlies the
pathology of ulcerative colitis.
INTRODUCTION
Inflammatory bowel disease (IBD) is a complex and debilitating
disorder that can be sub-classified into the distinct multifactorial
disorders Crohn’s disease (CD) and ulcerative colitis (UC) (Kaser
et al., 2010; Maloy and Powrie, 2011). While both are character-
ized by chronic relapsing pathogenic inflammation and intestinal
epithelial cell injury, they differ substantially in their clinical man-
ifestations. CD patients exhibit discontinuous lesions throughout
the entirety of the intestinal tract and disease pathology is closely
associated with a dysregulation of the antimicrobial peptide
(AMP) response (Fellermann et al., 2003; Neurath, 2014). A ge-
netic basis for CD susceptibility has been linked to genes
involved in autophagy and ER stress (e.g., Atg16l1 and Xbp1),
as well as microbial recognition (e.g., Nod2), in AMP-producing
Paneth cells (Adolph et al., 2013; Cadwell et al., 2008; Hugot
et al., 2001; Ogura et al., 2001). Interestingly, however, no major1444 Cell 163, 1444–1456, December 3, 2015 ª2015 Elsevier Inc.defects in AMP production have been observed in UC patients
(Nuding et al., 2007; Wehkamp et al., 2007), indicating distinct
mechanistic differences in disease etiology. Despite UC having
greater worldwide prevalence than CD (Danese and Fiocchi,
2011), surprisingly little is known about the specific underlying
host factors that drive susceptibility to disease. One unique
and defining feature of human UC pathology is major depletion
of mucin-producing goblet cells and the mucus layer, which cor-
relates with increased microbiota-induced colonic inflammation
and disease pathology (McCormick et al., 1990; Pullan et al.,
1994; Strugala et al., 2008; Trabucchi et al., 1986). Intriguingly,
the in vivo mechanisms responsible for this important clinical
observation during inflammation remain obscure.
Members of the IL-1 family of cytokines play critical roles in in-
testinal homeostasis and inflammation (Lopetuso et al., 2013;
Neurath, 2014; Saleh and Trinchieri, 2011). In particular, IL-18
has emerged as an indispensable factor in governing host-micro-
organism homeostasis and has been postulated to be a key
determining factor in IBD (Dinarello et al., 2013; Elinav et al.,
2011; Nakamura et al., 1989). IL-18 is initially synthesized as an
inactive precursor molecule that requires coordinated inflamma-
some activation of the cysteine protease caspase-1 to cleave
proIL-18 into a functional mature bioactive cytokine (Fantuzzi
et al., 1999; Martinon et al., 2002). Upon activation and release,
IL-18 is free to bind the IL-18 receptor alpha chain (IL-18R1)
and in cells co-expressing the IL-18R accessory protein (IL-
18Rap), ligand binding triggers receptor heterodimerization and
the formation of an intracellularMyd88 signaling platform (Adachi
et al., 1998; Born et al., 1998; Hoshino et al., 1999). This elicits the
recruitment of IRAK and TRAF6, facilitating activation of the in-
hibitor of kB (IkB) kinases (IKKs), IKKa and IKKb (Medzhitov
et al., 1998; Mercurio et al., 1997). In turn, IKKb can phosphory-
late IkBa, targeting the protein for proteasomal degradation
and allowing the NF-kB subunit p65 to translocate to the nucleus
to initiate diverse gene expression programs such as proinflam-
matory cytokine production and NOD-Like Receptor (NLR) upre-
gulation (Bauernfeind et al., 2009). As such, IL-18 signaling
requires tight regulation to prevent autoimmunity and this is
thought to be directly accomplished by the soluble decoy recep-
tor IL-18 binding protein (IL-18BP), as its transgene overexpres-
sion has been shown to neutralize IL-18 activity in vivo to prevent
hyper NF-kB activation and inflammation (Fantuzzi et al., 2003).
The use of IL-18- and IL-18R1-deficient mice identified IL-18
as a putative host molecule required to protect intestinal epithe-
lial cells from intestinal inflammation and colitis (Salcedo et al.,
2010). In support of a role for IL-18 in promoting intestinal epithe-
lial integrity and protection from acute experimental colitis, mice
deficient in the key processing subunits of IL-18, caspase 1, and
the NLRP3 inflammasome are also highly susceptible to disease
pathology (Dupaul-Chicoine et al., 2010; Zaki et al., 2010).
Administration of exogenous recombinant IL-18 rescues colitis
in the aforementioned and other inflammasome-deficient mice,
further supporting a protective role for IL-18 in colitis (Oficjalska
et al., 2015). In contrast, however, inhibition of IL-18 has also
been shown to instigate protection in experimental colitis, sup-
porting a pro-colitogenic role for IL-18 (Kanai et al., 2001; Sieg-
mund et al., 2001; Ten Hove et al., 2001). Such conflicting find-
ings have led to much controversy and discussion in the field,
and the true role of IL-18 in intestinal homeostasis and inflamma-
tion is still unresolved (Asquith and Powrie, 2010; Dinarello et al.,
2013; Gagliani et al., 2014; Siegmund, 2010).
Underlying this discourse is the fact that most previous work
studying the complete IL-18 deletion in mice is confounded by
IL-18 effect on colitogenic microbiota (Elinav et al., 2011;
Henao-Mejia et al., 2012), while equally important roles of IL-18
during inflammation are masked by dysbiosis. Compound-asso-
ciated phenotypic alterations in Il18/ mice such as metabolic
syndrome may further obscure the direct contribution of IL-18
to intestinal function (Netea et al., 2006). At present, no genetic
models exist to specifically dissect the role of IL-18 in colitis
risk, and the need for new genetic tools is therefore paramount.
To this end, we generated conditional knockout mice for both
IL-18 and IL-18R1 to delineate the direct involvement of IL-18 in
epithelial and hematopoietic cells to homeostasis and colitis.
Here, we show that IL-18 production, irrespective of its cellular
source, exacerbated colitis severity after administration of the
colitis-inducing agent dextran sodium sulfate (DSS). Deletion of
IL-18R in epithelial cells (Il18rD/EC) protected mice from devel-
oping colitis, suggesting that IL-18 directly disrupts epithelial
cell integrity during colitis. By deleting IL-18 binding protein
(Il18bp), the IL-18 negative regulator, we asked if increased
bioavailability of IL-18 would promote barrier function or rather
drive colitis. Remarkably, Il18bp/mice developed severe coli-
tis associated with progressive loss of mature goblet cells, which
could be reversed by specifically deleting the epithelial IL-18R in
these mice. Finally, we show that IL-18-mediated goblet cell
dysfunction precedes clinical disease manifestation and is
caused by a defect in terminal goblet cell maturation through
transcriptional regulation of goblet cell differentiation factors.
Taken together, these results uncover the direct role of IL-18 in
promoting goblet cell dysfunction during colitis, leading to break-
down of themucosal barrier. This study may therefore offer a ge-
netic understanding to the pathology of human ulcerative colitis.
RESULTS
Epithelial IL-18/IL-18R Signaling Promotes DSS-
Induced Colitis
IL-18 is a key mediator of intestinal homeostasis and inflamma-
tion, yet the cellular partners and molecular mechanisms drivingthese effects remain poorly understood. To delineate the com-
pound role of IL-18 in intestinal inflammation, we conditionally
deleted Il18 or Il18r1 in intestinal epithelial cells by generating
Villin-cre+;Il18fl/fl (hereafter called Il18D/EC) and Villin-cre+;Il18rfl/fl
(Il18rD/EC) mice (Figures S1A–S1D). To enable mechanistic
evaluation of IL-18’s microbiota-independent roles, throughout
this study knockout mice were compared to their cohoused
floxed (fl/fl) wild-type littermates. Indeed, bacterial 16S rRNA
sequencing confirmed equalized bacterial composition in both
Il18D/EC and Il18fl/fl littermates (Figure S2A). IL-18 production in
Il18D/EC total colon explants wasmarkedly reduced (Figure S1B),
confirming IECs as the major source of IL-18 under physiological
conditions (Takeuchi et al., 1997). Steady-state colon sections
did not show gross structural or cellular irregularities in Il18D/EC
or Il18rD/EC mice, including goblet cell maturation and tight junc-
tion formation, as determined by MUC2, b-catenin, and ZO-1
staining (FigureS3).Nevertheless, Il18D/ECmicewere surprisingly
resistant to colonic inflammation following administration ofDSS,
as reflected by reduced weight loss compared to Il18fl/fl litter-
mates (Figure 1A). Colonoscopy performed on day 7 post DSS
showed increased tissue damage in control Il18fl/fl mice,
measured by the degree of bleeding, colon wall granularity and
translucency, as well as stool consistency (Figure 1B). Similarly
to Il18D/EC mice, DSS-treated Il18rD/EC mice were protected
against weight loss, as compared to Il18rfl/fl littermates (Fig-
ure 1C). To more rigorously assess these effects in the presence
of a ‘‘colitogenic’’ microbiota, Il18rD/EC and Il18rfl/fl were co-
housed for 8 weeks with dysbiotic Il18/ mice in order to intro-
duce transmissible dominantly colitogenic bacteria (Elinav
et al., 2011) (Figure S2B). Despite an overall higher degree of
inflammation, Il18rD/EC mice had reduced weight loss and lower
colonoscopy score than control Il18rfl/fl mice (Figures 1D and
1E). Severe colitis and deterioration of tissue integrity in Il18rfl/fl
mice, but not in Il18rD/EC mice, was corroborated by histological
examination of distal colon sections performed on day 8 post
DSS (Figure 1F). These results suggest that IL-18 promotes the
pathology of DSS-induced colitis through a mechanism depen-
dent on its action on intestinal epithelial cells.
Hematopoietic/Endothelial IL-18, but Not IL-18R,
Promotes DSS-Induced Colitis
In addition to epithelial cells, IL-18 and IL-18R are also expressed
by various hematopoietic and endothelial cells, in particular un-
der inflammatory conditions (Siegmund, 2010). To address the
role of the IL-18 axis in these cells during colitis, we generated
Flk1-cre+;Il18fl/fl (Il18D/HE) and Flk1-cre+;Il18rfl/fl (Il18rD/HE) mice
in which Il18 or Il18r are specifically deleted in all hematopoietic
and endothelial cells (Figure S1B). As above, knockout mice
were compared to their cohoused floxed (fl/fl) wild-type litter-
mates, with both featuring similar microbiome configurations
(including the colitogenic Prevotellaceae species), thus enabling
us to study in detail the microbiome-independent contribution of
hematopoietic IL-18 to the intestinal pathology in these mice
(Figures S2C and S2D). Consistent with deletion of IL-18 in
epithelial cells, Il18D/HE mice were highly protected in DSS-
induced colitis, as indicated by reduced weight loss and colo-
noscopy scores compared to Il18fl/fl littermates (Figures 2A and
2B). In contrast, Il18rD/HE mice were susceptible to extensiveCell 163, 1444–1456, December 3, 2015 ª2015 Elsevier Inc. 1445
Figure 1. Epithelial IL-18/IL-18R Signaling Promotes DSS-Induced Colitis
To induce colitis, mice were administered 2% DSS in drinking water for 7 days.
(A) Weight loss of cohoused Il18fl/fl and Il18D/EC littermates (n = 11–14).
(B) Colonoscopy severity score of Il18fl/fl and Il18D/ECmice on day 7 and 11 post DSS (left) and representative endoscopic view of the mouse colon on day 7 post
DSS (right).
(C) Weight loss of cohoused Il18rfl/fl and Il18rD/EC littermates (n = 8).
(D) Littermate Il18rfl/fl and Il18rD/EC mice were cohoused with Il18/ mice for 8 weeks, after which DSS was administered and weight loss recorded (n = 7–13).
(E) Colonoscopy severity score of cohoused Il18rfl/fl, Il18rD/EC, and Il18/ on day 7.
(F) Representative H&E staining of distal colon sections obtained from cohoused Il18rfl/fl, Il18rD/EC, and Il18/ mice given water (top) or DSS (bottom) and as-
sessed on day 8. Note the disruption of crypt structure andmucosal immune cell infiltration in Il18rfl/fl and Il18/mice. Scale bar, 25 mm. Data are represented as
mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by unpaired Student’s t test.
See also Figures S1, S2, and S3.weight loss and tissue damage, to a comparable degree as their
Il18rfl/fl littermates (Figures 2C and 2D). Histology performed on
day 8 post DSS confirmed similar extent of colitis in both Il18rfl/fl
and Il18rD/HEmice (Figure 2E). These results further demonstrate1446 Cell 163, 1444–1456, December 3, 2015 ª2015 Elsevier Inc.that irrespective of its cellular source, IL-18 production during
colitis drives disease progression. Colitis severity, however, is
not exacerbated by IL-18R signaling in hematopoietic and/or
endothelial cells, in contrast to what is observed in epithelial
Figure 2. Hematopoietic/Endothelial IL-18,
but Not IL-18R, Promotes DSS-Induced
Colitis
(A) Weight loss of cohoused Il18fl/fl and Il18D/HE
littermates treated with 2% DSS for 7 days (n = 4).
(B)Colonoscopyseverityscoreof Il18fl/fland Il18D/HE
mice on day 7 and 11.
(C) Weight loss of cohoused Il18rfl/fl and Il18rD/HE
littermates (n = 6).
(D) Colonoscopy severity score of Il18rfl/fl and
Il18rD/HE mice on day 7.
(E) Representative H&E staining of distal colon
sections obtained from cohoused Il18rfl/fl and
Il18rD/HE mice given water (top) or DSS (bottom)
and assessed on day 8. Scale bar, 25 mm. Data are
represented as mean ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001; by unpaired Student’s t test.
See also Figures S1, S2, and S3.cells. Together, these data show that the target of IL-18-medi-
ated pathology is the epithelium.
Hyperactive IL-18 Signaling Drives Colitis and Goblet
Cell Depletion in Il18bp/ Mice
IL-18 is negatively regulated by the IL-18 binding protein (IL-
18BP), which serves as a decoy receptor and prevents IL-18
association with IL-18R (Novick et al., 1999). While basal expres-Cell 163, 1444–1456, Dsion levels of Il18bp in the steady-state
colonwere low, it was highly induced dur-
ing the course of colitis, returning to base-
line levels following recovery (Figure 3A).
To better understand the mechanism by
which IL-18 enhances susceptibility to
colitis, we generated mice with hyperac-
tive IL-18 signalingbydeleting Il18bp (Fig-
ure S1E). Il18bp expression was unde-
tectable in Il18bp/ mice, whereas the
expression of neighboring genes was un-
affected (Figure S1F). Furthermore, in the
steady-state Il18bp/ mice had equal-
ized flora compared to their wild-type
(WT) littermates (Figure S2E) and dis-
played normal goblet cell development
and tight junction structure (Figure S3).
Although Il18 mRNA expression was
comparable in WT and Il18bp/ mice,
the active secreted form of IL-18 was
elevated in Il18bp/ colonexplant super-
natants, both in the steady state and
following DSS treatment (Figure 3B). Dur-
ing DSS colitis, Il18bp/mice developed
rapid and severe morbidity associated
with extensive bleeding and tissue dam-
age (Figures 3C and 3D). Extensive tissue
deterioration and colitis were also evident
in histological sections of Il18bp/ mice
but not of theirWT littermate controls (Fig-
ure 3E). Remarkably, Il18bp/ mice suf-
fered an overwhelming loss of mucus-producing goblet cells
(Figure 3E). The absence of mature goblet cells and associated
mucus layer in Il18bp/ mice was verified by AB/PAS staining
(Figure 3E). Goblet cell enumeration in histological sections
showed a dramatic decrease in goblet cell counts in Il18bp/
mice compared to WT mice at day 8 post DSS (Figure 3E).
Decreased goblet cell counts were also noted in Il18fl/fl and
Il18rfl/fl mice compared to Il18D/EC or Il18rD/EC littermatesecember 3, 2015 ª2015 Elsevier Inc. 1447
Figure 3. Hyperactive IL-18 Signaling Drives Colitis and Goblet Cell Loss in Il18bp/ Mice
(A) Wild-type (WT) mice were treated with 2% DSS in drinking water and Il18bp mRNA expression in the distal colon was measured over 14 days.
(B) IL-18 mRNA expression in distal colon (left) and protein secretion in colonic explants (right) of il18bp/ and WT littermates.
(C) Weight loss following DSS treatment in cohoused WT and Il18bp/ littermates (n = 10).
(D) Colonoscopy severity score of WT and Il18bp/ mice.
(E) Representative H&E and AB/PAS staining of distal colon sections obtained from cohoused WT (top) and Il18bp/ (bottom) littermates on day 8 post DSS
treatment. Asterisksmark example goblet cells. Right, enumeration of goblet cells in histological sections from cohousedWT and Il18bp/ littermates. Scale bar,
25 mm. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by unpaired Student’s t test.
See also Figures S1, S2, S3, and S4.following DSS (Figure S4A). These results suggest that hyper-IL-
18 signaling leads to exacerbated colitis associated with mature
goblet cell depletion.
Deletion of Epithelial IL-18R Rescues Goblet Cell Loss
and Colitis in Il18bp/ Mice
We next asked whether goblet cell loss and the increased colitis
severity observed in Il18bp/ mice arise as a general conse-
quence of immune cell activation and inflammation due to hyper-
active IL-18, or is rather directly dependent on IL-18 signaling
mediated perturbation of epithelial cell function. To address
this question in vivo, we generated Il18bp/;Il18rD/EC double
knockout mice, with the hypothesis that if increased colitis in
Il18bp/ mice is a result of hyper immune activation, loss of
IL-18R signaling in epithelial cells will not affect the course of dis-
ease. However, if increased colitis in Il18bp/mice is a result of
epithelial cell dysregulation, loss of IL-18R signaling in epithelial1448 Cell 163, 1444–1456, December 3, 2015 ª2015 Elsevier Inc.cells may rescue the pathology in Il18bp/mice. Following DSS
treatment, Il18bp/;Il18rD/EC mice were dramatically protected
from weight loss in comparison to Il18bp/ littermates, to the
same level as Il18bp+/+ WT littermates (Figure 4A). This corre-
lated with decreased intestinal bleeding and tissue damage in
Il18bp/;Il18rD/EC mice, assessed by colonoscopy at day 7
post DSS (Figure 4B). Upon dissection at day 8 post DSS,
Il18bp/ mice exhibited macroscopic indications of severe in-
testinal inflammation with extensive bleeding throughout the
intestine and significant shortening of the colon, while the intes-
tines of Il18bp/;Il18rD/EC mice appeared normal (Figure 4C).
Colon tissue sections obtained at day 8 post DSS revealed
reduced immune cell infiltration and maintenance of structural
integrity in Il18bp/;Il18rD/EC mice, while Il18bp/ mice
showed extensive tissue pathology (Figure 4D). Importantly,
goblet cells were completely recovered in Il18bp/;Il18rD/EC
mice, representing the baseline levels observed in WT mice, as
Figure 4. Deletion of Epithelial IL-18R Rescues Goblet Cell Loss and Colitis in Il18bp/ Mice
(A) Weight loss of cohoused Il18bp/, Il18bp/;Il18rD/EC, and WT littermates treated with 2% DSS for 7 days (n = 10–14).
(B) Colonoscopy severity score of Il18bp/ and Il18bp/;Il18rD/EC littermates on day 7.
(C) Gross pathology of colons on day 8 post DSS. Note the extensive shortening, bleeding, and diarrhea in Il18bp/ mice.
(D) Representative H&E and AB/PAS staining of distal colon sections obtained from cohoused Il18bp/ (top) and Il18bp/;Il18rD/ECmice (bottom) on day 8 post
DSS treatment. Asterisks mark example goblet cells. Scale bar, 25 mm. Data are represented as mean ± SEM. **p < 0.01; ***p < 0.001; ****p < 0.0001 by unpaired
Student’s t test.demonstrated by both H&E and AB/PAS staining (Figure 4D;
compare to Figure 3E). These results indicate that goblet cell
loss and increased susceptibility to colitis are a direct conse-
quence of increased IL-18 signaling in intestinal epithelial cells.
Hyperactive IL-18 Signaling Prevents Goblet Cell
Maturation Prior to Colitis
To determine whether the observed goblet cell dysfunction is a
cause rather than a consequence of inflammation, we examined
histological colon sections from Il18bp/ mice at day 4 post
DSS, preceding significant weight loss and clinical symptoms
of colitis. Although goblet cells were readily identified by H&E
staining in Il18bp/mice, AB/PAS staining indicated decreased
abundance of mature PAS+ goblet cells in Il18bp/ mice
compared to WT or Il18bp/;Il18rD/EC littermates (Figure 5A).Goblet cell maturation was further assessed by staining for fuco-
sylated glycoproteins with the lectin Ulex europaeus agglutinin-1
(UEA-1) and the abundant goblet cell mucin MUC2, both of
which accumulate as goblet cells mature. Il18bp/ mice ex-
hibited an increase of immature goblet cells, determined by
low area MUC2 staining (<10 mm in diameter) in UEA-1lo/ cells
and decrease in large mature MUC2+UEA-1bright goblet cells
compared to Il18bp/;Il18rD/EC mice (Figure 5B). The mature/
immature goblet cell ratio on day 4 post DSS decreased to
0.58 in Il18bp/ mice compared to 1.39 in Il18bp/;Il18rD/EC
mice and 1.84 in Il18bp+/+ (WT) mice (Figures 5C, S4B, and
S4C). As noted above, mature goblet cells were markedly
depleted in Il18bp/ mice on day 8 post DSS; however, small
MUC2+UEA-1+/ cells were still highly represented, notably at
the lower half of the crypt (Figure S4D). To determine whetherCell 163, 1444–1456, December 3, 2015 ª2015 Elsevier Inc. 1449
(legend on next page)
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dysregulation of goblet cell maturation reflects a transcriptional
imbalance, we measured expression of transcription factors
involved in goblet cell differentiation and maturation. Whereas
no change was noted in the secretory lineage differentiation fac-
torsMath1 (Hath1; Atoh1) andHes1, expression of the goblet cell
differentiation/maturation factors Gfi1, Spdef, and Klf4 was
markedly inhibited in Il18bp/ mice (Figure 5D). These results
suggest that IL-18 promotes colitis by preventing functional
goblet cell maturation through regulation of the goblet cell tran-
scriptional maturation program.
IL-18 Directly Controls Goblet Cell Maturation and
Colitis
We finally assessed the direct role of IL-18 in goblet cell dysfunc-
tion leading to colitis, by injecting recombinant IL-18 protein toWT
mice during the course of DSS administration. Disease severity
was increased in mice receiving daily IL-18 injections, as deter-
mined by weight loss and macroscopic examination of the colon
atday8postDSS (Figures6Aand6B). In linewithour observations
in Il18bp/ mice, AB/PAS staining showed gradual decrease in
the abundance of mature PAS+ goblet cells in mice receiving IL-
18 compared to PBS (Figure 6C). The state of goblet cell matura-
tion was corroborated in colon sections obtained following 5 daily
injections prior to weight loss and clinical symptoms of colitis,
demonstrating an IL-18-mediated block in goblet cell maturation
(Figures 6D and 6E). The ratio of mature/immature goblet cell
decreased further in IL-18-injected mice on day 8 (Figures S4D
and S4E). IL-18 injection was sufficient to reduce Gfi1, Spdef,
andKlf4geneexpression in isolated IECs, further supportingdirect
regulation of goblet cell maturation by IL-18 (Figure 6F). These re-
sults suggest that elevated IL-18 production during inflammation
is responsible for dysregulated goblet cell maturation.
DISCUSSION
Despite great strides in our understanding of IL-18 over the past
15 years, its precise contributions to host homeostasis, intestinal
inflammation, and its overall relevance to IBD still remain contro-
versial and elusive. On one hand, complete loss of IL-18 (or IL-
18R) predisposes mice to increased intestinal epithelial damage
and fosters an altered inflammatory environment that potentiates
intestinal tumor formation (Salcedo et al., 2010; Takagi et al.,
2003). This could be explained, at least in part, by the recently
identified role of IL-18 in controlling the outgrowth of colitogenic
bacterial species (Elinav et al., 2011). On the other hand, IL-18 is
a potent proinflammatory cytokine with the ability to promote co-
litis through the induction of inflammatory mediators such TNFa
and chemokines (Sivakumar et al., 2002; Ten Hove et al., 2001).Figure 5. Hyperactive IL-18 Signaling Prevents Goblet Cell Maturation
(A) Representative H&E and AB/PAS staining of distal colon sections obtained
treatment prior to onset of colitis. Note reduction in PAS+ mature goblet cells in
(B) Epifluorescence images (left, top right panels) and confocal stacks (bottom rig
the fucose-binding lectin UEA-1 and anti-MUC2. Scale bar, 150 mm.
(C) Enumeration of immature andmature goblet cells in distal colon sections staine
area (<10 mm in diameter) MUC2 staining, and mature goblet cells were scored a
(D) Distal colon samples were obtained on day 8 post DSS and used for gene ex
****p < 0.0001 by unpaired Student’s t test.
See also Figure S4.The role of IL-18 in intestinal homeostasis and inflammation and
its mechanistic segregation from microbiota-dependent func-
tions therefore remained unresolved.
Previous interpretations of IL-18 functionality have been
limited by the lack of precise genetic models required to system-
atically determine its roles in intestinal biology. Therefore, IL-18
function has been inferred from complete deletion of IL-18, in-
flammasomes, caspase 1/11, or the multifunctional adaptor pro-
tein ASC. Such studies have led to the conclusion that epithelial-
derived IL-18 is required to promote barrier integrity during early
inflammation, as acute treatment with recombinant IL-18 during
early colitis promotes epithelial proliferation in inflammasome-
deficient mice, rescuing intestinal pathology (Dupaul-Chicoine
et al., 2010; Zaki et al., 2010). However, extrapolation of direct
IL-18 functionality from these models should be approached
with caution. First, deficiency of NLRP3, which is highly ex-
pressed in the myeloid compartment, results in numerous
phenotypic alterations beyond IL-18 processing. Most obvious
is an inherent defect in processing the closely related and equally
important cytokine IL-1b. Like IL-18, IL-1b is also thought to
mediate a dichotomous role in intestinal homeostasis and
inflammation (Bamias et al., 2012; Lopetuso et al., 2013).
Notably, bonemarrow chimera experiments have shown that he-
matopoietic-derived IL-1b is also sufficient to rescue epithelial
cell damage and promote epithelial restitution during experi-
mental colitis (Bersudsky et al., 2014). Therefore, in NLRP3-defi-
cient mice, which harbor defects in IL-1 family member matura-
tion, IL-18 may compensate for the lack of IL-1b; however,
whether this occurs physiologically (or at physiologically relevant
levels of IL-18) remains unclear. In addition, caspase 1 plays a
key role in the clearance of intracellular intestinal pathogens
through the regulated cell death process of pyroptosis (Miao
et al., 2010). Although the role of pyroptosis in colitis is still under
investigation, the use of pyroptosis-defective mice to examine
the specific IL-18 functionality in the intestine proves problem-
atic. The study of direct functions of IL-18 in the intestine is
further complicated by NLRP6 regulation of dysbiosis and the
outgrowth of pathogenic intestinal microbial communities (Elinav
et al., 2011). As demonstrated by Levy et al. (2015) in this issue of
Cell, IL-18 processing by the NLRP6 inflammasome shapes the
steady-state host-microbiome interface by regulating the down-
stream anti-microbial peptide (AMP) landscape, thereby main-
taining intestinal homeostasis. Normally, this axis is controlled
by indigenous microbiota-modulated metabolites. However, it
can also be directly subverted by inflammasome suppressing
metabolites derived from a disease-causing microbiota, which
hijacks this pathway, thereby facilitating dysbiosis development
and persistence in an invaded host. This highlights thePrior to Colitis
from WT, Il18bp/, and Il18bp/;Il18rD/EC littermates on day 4 post DSS
Il18bp/ mice. Scale bar, 25 mm.
ht panels) of distal colon sections obtained on day 4 post DSS and stained with
d as in (B). Immature goblet cells were scored as UEA-1lo/ cells containing low
s cells containing large area (>10 mm in diameter) MUC2+UEA-1bright staining.
pression analysis by qPCR. Data are represented as mean ± SEM. *p < 0.05;
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Figure 6. IL-18 Directly Controls Goblet Cell Maturation and Colitis
(A) WTmice received daily intraperitoneal (i.p.) injections of 1 mg recombinant IL-18 or PBS during the course of 7 day 2%DSS administration and weight loss was
recorded (n = 5).
(B) Gross pathology of colons on day 8 post DSS. Note reduction in colon length following IL-18 treatment.
(C) Representative AB/PAS staining of distal colon sections obtained on day 5 or 8 post DSS treatment fromWT littermates receiving recombinant IL-18 or PBS.
Note reduction in PAS+ mature goblet cells in mice receiving recombinant IL-18. Scale bar, 25 mm.
(legend continued on next page)
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importance of using cohoused littermate control mice, as in the
present study, as they harbor near identical bacterial species
enabling distinction of the genetic contribution of IL-18 from
that of flora driven inflammation.
In this study, we show that during inflammation, not only is
IL-18 production in intestinal epithelial and hematopoietic cells
not required for protection against experimental colitis, IL-18
signaling in epithelial cells amplifies intestinal damage. This
pathogenic role of IL-18 correlates with clinical observations
whereby an increase in both epithelial and hematopoietic IL-18
expression and cytokine bioreactivity have been demonstrated
in patients with increased severity of IBD (Monteleone et al.,
1999; Pizarro et al., 1999). However, the mechanism through
which this upregulation of IL-18 in the intestine may contribute
to increased disease severity was unknown. An emerging reali-
zation in the complexity of IBD is that pathology is not wholly
shaped by a dysregulated immune response but highly depen-
dent on an intact mucosal barrier and coordinated cross talk
between the intestinal epithelial and immune cells with the mi-
crobiota (Kaser et al., 2011; Schreiber et al., 2005; Xavier and
Podolsky, 2007). One possible mechanism to explain this asso-
ciation is that increased IL-18 release from epithelial cells acts on
resident immune cell to upregulate IL-18 and other proinflamma-
tory mediators, which induce endothelial VCAM-1 expression to
enhance immune cell infiltration into the mucosa and together
trigger severe auto-inflammation. In support of this model, we
show that deletion of IL-18 production in the hematopoietic
compartment results in significant amelioration of intestinal dam-
age during colitis. However, deletion of IL-18R signaling in the
hematopoietic compartment fails to rescue mice from DSS-
induced inflammation. This suggests that the pathology driven
by IL-18 does not occur via signaling in hematopoietic cells, in
line with previous reports (Dupaul-Chicoine et al., 2010; Malvin
et al., 2012; Saleh and Trinchieri, 2011; Zaki et al., 2010). Rather,
we found that deletion of the IL-18R from intestinal epithelial cells
dramatically protects mice fromDSS-induced colitis, suggesting
that elevated IL-18 expression during colitis is directly patho-
genic to the epithelial cell barrier.
Ulcerative colitis is characterized by mucosal barrier dysfunc-
tion, most notably in epithelial goblet cells andmucus production
(Danese and Fiocchi, 2011; Gersemann et al., 2009; McCormick
et al., 1990; Pullan et al., 1994; Trabucchi et al., 1986). As goblet
cell secretion of protective mucins, trefoil factors, and other pro-
teins is essential for barrier integrity and for preventing micro-
flora-driven intestinal inflammation, such dysregulation underlies
the pathology exhibited in UC patients. In order to investigate
how IL-18 may specifically contribute to intestinal barrier break-
down during DSS colitis, we deleted its decoy receptor inhibitor,
IL-18BP. Interestingly, Il18bp/ mice were characterized by
increased colitis severity and lethality associated with major
depletion of mature goblet cells, which was reversed in(D) Epifluorescence images (left, top right panels) and confocal stacks (bottom rig
UEA-1 and anti-MUC2. Scale bar, 150 mm.
(E) Enumeration of immature and mature goblet cells in distal colon sections sta
(F) Distal colon samples were obtained on day 8 post DSS and used for gene ex
**p < 0.01; ****p < 0.0001 by unpaired Student’s t test.
See also Figure S4.Il18bp/;Il18rD/EC double knockout mice. Thus, excessive
IL-18 signaling on the epithelium leads to progressive depletion
of goblet cells and may represent a major risk factor for intestinal
inflammation and UC. As severe intestinal inflammation has pre-
viously been suggested to result in goblet cell depletion (Berg-
strom et al., 2008), we analyzed mice during preclinical manifes-
tation of colitis in order to exploremechanistically if IL-18was the
key determining factor governing goblet cell loss and risk for co-
litis. Whereas we observed no discernible differences in goblet
cell numbers at preclinical time points, we instead discovered
that IL-18 promotes disequilibrium in the state of goblet cell
development and maturation, decreasing the pool of functional
mature goblet cells.
Studies on the transcriptional regulation of intestinal lineage
determination have identified the factors controlling goblet cell
differentiation and maturation (McCauley and Guasch, 2015).
Notch1 signaling drives epithelial progenitor cell specification
to absorptive enterocytes and inhibits secretory cell differentia-
tion via the Hes1 transcription factor (Fre et al., 2005; Jensen
et al., 2000), whereas Notch1 inhibition results in robust conver-
sion of proliferating crypt progenitors into terminally differenti-
ated goblet cells (van Es et al., 2005). Below a threshold of
Notch1 signal, upregulation of Math1 (also known as Hath1,
Atoh1) governs commitment of progenitor cells to the epithelial
secretory cell lineages, including goblet cells, Paneth cells, and
neuroendocrine cells (Yang et al., 2001). The transcriptional
repressor Gfi1 functions downstream of Math1 to control intesti-
nal secretory cell differentiation, specification, and maintenance
and is required for goblet and Paneth cell development (Shroyer
et al., 2005). The transcription factors Spdef and Klf4 in turn con-
trol goblet cell development and maturation downstream to Gfi1
and are essential for mucosal barrier protection (Gregorieff et al.,
2009; Katz et al., 2002; Noah et al., 2010). Analysis of the lineage
commitment transcription factors Hes1 and Math1 in the intesti-
nal epithelium of mice with hyperactive IL-18 did not indicate
dysregulation at the lineage specification level. Conversely how-
ever, the downstream secretory lineage transcription factor Gfi1
and the terminal goblet cell maturation effectors Spdef and Klf4
were markedly downregulated by IL-18. Importantly, all three
transcription factors are required to be constitutively expressed
in mature goblet cells and loss of either Gfi1, Spdef, or Klf4
expression was shown to result in loss of mature goblet cells
(Gregorieff et al., 2009; Katz et al., 2002; Shroyer et al., 2005).
These data highlight an unexpected role for IL-18 signaling in
directly modulating goblet cell maturation and fate downstream
to secretory lineage commitment during intestinal inflammation.
In conclusion, we propose that a strict equilibrium of epithelial
IL-18 signaling must be maintained in order to preserve its ho-
meostatic functions while preventing progressive loss of mature
goblet cells and increased risk of colitis. This work suggests that
IL-18 targeting or specific targeting of epithelial IL-18R mayht panels) of distal colon sections obtained on day 5 post DSS and stained with
ined as in (D). Immature and mature goblet cells were scored as in Figure 5C.
pression analysis by qPCR. Data are represented as mean ± SEM. *p < 0.05;
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represent a novel strategy to prevent the pathologic breakdown
of the mucosal barrier in human ulcerative colitis.
EXPERIMENTAL PROCEDURES
Mice
Conditional knockout mice with floxed IL-18 alleles or floxed IL-18R alleles
were generated using standard homologous gene recombination techniques
(Rongvaux et al., 2014). Il18/ mice have been previously reported (Takeda
et al., 1998). Il18bp deletion was generated using Cas9/CrispR technology
as described (Wang et al., 2013). All experiments were performed using co-
housed littermate control mice. For transmissible dysbiosis cohousing exper-
iments, littermate Il18rfl/fl and Il18rD/EC mice and age and gender matched
Il18/ mice were cohoused at ratios of 1:1:1 for 8 weeks. All animal experi-
mentation was performed in compliance with Yale Institutional Animal Care
and Use Committee protocols.
Experimental Colitis
For acute experimental colitis induction, mice were administered 2% DSS
(M.W. = 36,000–50,000 Da; MP Biomedicals) in their drinking water ad libitum
for 7 days, followed by regular drinking water. According to the animal proto-
col, mice were sacrificed if they lost more than 30% of their initial body weight.
Colonoscopy
Colonoscopy was performed using a high resolution mouse video endoscopic
system (‘‘Coloview,’’ Carl Storz). The severity of colitis was blindly scored us-
ing MEICS (Murine Endoscopic Index of Colitis Severity) based on four param-
eters: granularity of mucosal surface, vascular pattern, translucency of the
colon mucosa, and stool consistency (Becker et al., 2006).
Histology
Colons were fixed in Bouin’s medium and embedded in paraffin. Blocks were
serially sectioned along the cephalocaudal axis of the gut to the level of the
lumen; the next 5 mm-thick section was stained with H&E. For goblet cell
and mucus layer preservation ex vivo, immediately after excision, colons
were submerged in Ethanol–Carnoy’s fixative at 4C for 2 hr and then placed
into 100% ethanol. Fixed colon tissues were embedded in paraffin and cut into
5-mm sections. Tissues were stained with Alcian blue/PAS. Images were
acquired with Leica DMI6000B inverted microscope, and data were analyzed
using the LAS-AF software.
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